Servier gets FDA clearance for Asparlas
The Food and Drug Administration has approved Servier Pharmaceuticals’ Asparlas (calaspargase pegol-mknl).
Asparlas is an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years old.
This new product provides for a longer interval between doses compared to other available pegaspargase products.
The recommended calaspargase pegol-mknl dose is 2,500 units/m2 intravenously administered at a minimum dosing interval of every 21 days.
Asparlas is an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years old.
This new product provides for a longer interval between doses compared to other available pegaspargase products.
The recommended calaspargase pegol-mknl dose is 2,500 units/m2 intravenously administered at a minimum dosing interval of every 21 days.